Relapsing Remitting Multiple Sclerosis (RRMS) Global Clinical Trials Review, H2, 2016

GlobalData
520 Pages - GLDATA56855
$2,500.00

Summary

GlobalData's clinical trial report, “Relapsing Remitting Multiple Sclerosis (RRMS) Global Clinical Trials Review, H2, 2016" provides an overview of Relapsing Remitting Multiple Sclerosis (RRMS) clinical trials scenario. This report provides top line data relating to the clinical trials on Relapsing Remitting Multiple Sclerosis (RRMS). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Companies Mentioned

Biogen, Inc.
Novartis AG
Teva Pharmaceutical Industries Ltd.
Bayer AG
E. Merck KG
Sanofi
Pfizer Inc.
GlaxoSmithKline Plc
F. Hoffmann-La Roche Ltd.
AbbVie Inc.

'

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Five Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Relapsing Remitting Multiple Sclerosis (RRMS) to Central Nervous System Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Relapsing Remitting Multiple Sclerosis (RRMS) to Central Nervous System Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials 27
Prominent Drugs 28
Latest Clinical Trials News on Relapsing Remitting Multiple Sclerosis (RRMS) 29
Jun 28, 2016: Coherus Announces Positive Phase 2B Efficacy Data On Novel Oral Therapy In Relapsing Remitting Multiple Sclerosis 29
Jun 03, 2016: Novartis data show Gilenya had significantly greater patient retention compared to iDMTs in relapsing-remitting MS 29
Jun 03, 2016: Arrien Pharmaceuticals Initiated Phase I Clinical Trials of ARN-6039 as a New Agent for Treatment of Multiple Sclerosis 30
May 31, 2016: GeNeuro Announces First Patients Treated in Phase 2b Study for Multiple Sclerosis 31
May 25, 2016: Merck to Present Data on Rebif (interferon beta-1a) for Multiple Sclerosis at 2nd Congress of the European Academy of Neurology 31
May 25, 2016: Merck to Present Data on Cladribine Tablets for Multiple Sclerosis at 2nd Congress of the European Academy of Neurology 32
May 03, 2016: TG Therapeutics Launches First Clinical Trial in Multiple Sclerosis (MS) for TG-1101 (Ublituximab) 33
Apr 22, 2016: Daclizumab Demonstrates Significant, Sustained Improvements In Cognition Compared To Interferon Beta-1A IM 33
Apr 20, 2016: Data Presented at AAN Highlight Impact of ZINBRYTA (Daclizumab HYP) on Cognitive Outcomes and the Reversibility of Its Targeted Mechanism of Action 34
Clinical Trial Profile Snapshots 36
Appendix 517
Abbreviations 517
Definitions 517
Research Methodology 518
Secondary Research 518
About GlobalData 519
Contact Us 519
Disclaimer 519
Source 520

List of Tables
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, Global, Clinical Trials by Region, 2016* 6
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 12
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 13
Proportion of Relapsing Remitting Multiple Sclerosis (RRMS) to Central Nervous System Clinical Trials, G7 Countries (%), 2016* 14
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Relapsing Remitting Multiple Sclerosis (RRMS) to Central Nervous System Clinical Trials, E7 Countries (%), 2016* 17
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, Global, Clinical Trials by Phase, 2016* 20
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28

List of Figures
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 12
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 13
Proportion of Relapsing Remitting Multiple Sclerosis (RRMS) to Central Nervous System Clinical Trials, G7 Countries (%), 2016* 14
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Relapsing Remitting Multiple Sclerosis (RRMS) to Central Nervous System Clinical Trials, E7 Countries (%), 2016* 17
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28
GlobalData Methodology 518

$2,500.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838



Browse All Reports